Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China
- 202 Downloads
Background and objectives
The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China.
Genotyping of CYP2C19 and MACE of 934 ACS patients with PCI on clopidogrel maintenance therapy were analyzed. Patients who carried loss-of-function CYP2C19 were treated with a 150-mg maintenance dose of clopidogrel or 90 mg of ticagrelor antiplatelet therapy, and patients who were non-carriers received clopidogrel therapy daily at a maintenance dose of 75 mg and the patients were followed-up for at least 12 months. The primary efficacy endpoint was a composite of cardiovascular death, myocardial infarction, and target vessel revascularization and stroke.
The allelic frequency of CYP2C19*2 and CYP2C19*3 of Hakka patients in the current study was 31.64 and 5.19%, respectively. The CYP2C19 wild-type homozygotes (*1/*1) were the most predominant among the patients (40.36%), followed by the CYP2C19*2 heterozygotes (*1/*2) (40.26%). The distribution of CYP2C19 phenotypes was divided into extensive metabolizers (EM; 40.36%), intermediate metabolizers (IM; 45.61%), and poor metabolizers (PM; 14.03%). Based on the genotype-guided antiplatelet therapy, there was no significant association between the carrier status and the clinical outcome at 1, 6, and 12 months. In addition, no significant difference in the rates of bleeding was found among the three groups. After logistic regression analysis, hypertension was the only independent predictor of cardiovascular events (relative risk, 1.501; 95% CI, 1.011 to 2.229; P = 0.044).
Our results shed new light on the important benefit of testing CYP2C19 polymorphisms before prescribing clopidogrel in patients treated with drug-eluting stent implantation after PCI. The testing may help to optimize pharmacotherapy effectiveness by providing individualized treatment to the Chinese population. Our findings mandate further studies aimed at initiating genome-based personalized antiplatelet therapy in a Hakka population in southern China.
KeywordsCytochrome P450 (CYP) 2C19 Genetic polymorphism Acute coronary syndrome Drug-eluting stent implantation Clopidogrel Cardiovascular events
Pingsen Zhao conceived and designed the experiments; Zhixiong Zhong, Qifeng Zhang, Bin Li, Cunren Li, Zhidong Liu, Min Yang, Wei Zhong, and Xuebo He collected the clinical data and samples; Jingyuan Hou, Hesen Wu, and Miaocai Zhong performed the experiments; Pingsen Zhao, Zhixiong Zhong, and Jingyuan Hou analyzed the data and wrote the paper. All authors have read and approved the final manuscript.
Compliance with ethical standards
The study protocol was in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethics Committee of Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University. Written informed consent was obtained from all enrolled patients, and their privacy was strictly protected.
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354(16):1706–1717. https://doi.org/10.1056/NEJMoa060989 CrossRefPubMedGoogle Scholar
- 4.Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16):1821–1830. https://doi.org/10.1001/jama.2010.1543 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ (2008) Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 48(4):475–484. https://doi.org/10.1177/0091270008315310 CrossRefPubMedGoogle Scholar
- 7.Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108(7):2244–2247. https://doi.org/10.1182/blood-2006-04-013052 CrossRefPubMedGoogle Scholar
- 8.Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM (2010) ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 56(4):321–341. https://doi.org/10.1016/j.jacc.2010.05.013 CrossRefPubMedGoogle Scholar
- 9.Osnabrugge RL, Head SJ, Zijlstra F, ten Berg JM, Hunink MG, Kappetein AP, Janssens AC (2015) A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. Genet Med 17(1):3–11. https://doi.org/10.1038/gim.2014.76 CrossRefPubMedGoogle Scholar
- 10.Zhang L, Yang J, Zhu X, Wang X, Peng L, Li X, Cheng P, Yin T (2015) Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention—a systematic review and meta-analysis. Thromb Res 135(3):449–458. https://doi.org/10.1016/j.thromres.2014.12.007 CrossRefPubMedGoogle Scholar
- 11.Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomas M, Masia R, Marrugat J, Brugada R, Elosua R (2012) Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 98(2):100–108. https://doi.org/10.1136/hrt.2011.227652 CrossRefPubMedGoogle Scholar
- 12.Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8):849–857. https://doi.org/10.1001/jama.2009.1232 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Bergmeijer TO, Janssen PW, Schipper JC, Qaderdan K, Ishak M, Ruitenbeek RS, Asselbergs FW, van ‘t Hof AW, Dewilde WJ, Spano F, Herrman JP, Kelder JC, Postma MJ, de Boer A, Deneer VH, ten Berg JM (2014) CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am Heart J 168(1):16–22 e11. https://doi.org/10.1016/j.ahj.2014.03.006 CrossRefPubMedGoogle Scholar
- 14.Sorich MJ, Rowland A, McKinnon RA, Wiese MD (2014) CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet 7(6):895–902. https://doi.org/10.1161/CIRCGENETICS.114.000669 CrossRefPubMedGoogle Scholar
- 15.Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, Noh GJ, Njau R, Close S, Wise S, Hockett R (2010) Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 50(8):929–940. https://doi.org/10.1177/0091270009355161 CrossRefPubMedGoogle Scholar
- 19.Tanguay JF, Bell AD, Ackman ML, Bauer RD, Cartier R, Chan WS, Douketis J, Roussin A, Schnell G, Verma S, Wong G, Mehta SR (2013) Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol 29(11):1334–1345. https://doi.org/10.1016/j.cjca.2013.07.001 CrossRefPubMedGoogle Scholar
- 20.Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, ZH X, Zhou HH (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 281(1):604–609PubMedGoogle Scholar
- 22.Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94(3):317–323. https://doi.org/10.1038/clpt.2013.105 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LL A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 98(2):127–134. https://doi.org/10.1002/cpt.147 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7(1):59–64. https://doi.org/10.1097/00008571-199702000-00008 CrossRefPubMedGoogle Scholar
- 26.Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, Wennerholm A, Johansson I, Dahl ML, Bertilsson L, Gustafsson LL (1998) Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 64(4):391–401. https://doi.org/10.1016/S0009-9236(98)90070-4 CrossRefPubMedGoogle Scholar
- 29.Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38(4):402–408. https://doi.org/10.1038/clpt.1985.194 CrossRefPubMedGoogle Scholar
- 30.Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660):309–317. https://doi.org/10.1016/S0140-6736(08)61845-0 CrossRefPubMedGoogle Scholar
- 31.Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Buttner HJ, Neumann FJ (2008) Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51(20):1925–1934. https://doi.org/10.1016/j.jacc.2007.12.056 CrossRefPubMedGoogle Scholar
- 32.Xie X, Ma YT, Yang YN, Li XM, Ma X, ZY F, Zheng YY, Chen BD, Liu F (2013) CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. PLoS One 8(3):e59344. https://doi.org/10.1371/journal.pone.0059344 CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Depta JP, Lenzini PA, Lanfear DE, Wang TY, Spertus JA, Bach RG, Cresci S (2015) Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J 15(1):20–25. https://doi.org/10.1038/tpj.2014.28 CrossRefPubMedGoogle Scholar
- 36.Cresci S, Depta JP, Lenzini PA, Li AY, Lanfear DE, Province MA, Spertus JA, Bach RG (2014) Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. Circ Cardiovasc Genet 7(3):277–286. https://doi.org/10.1161/CIRCGENETICS.113.000303 CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Shechter M (2003) Atorvastatin and the ability of clopidogrel to inhibit platelet aggregation. Circulation 107(22):210e–2210. https://doi.org/10.1161/01.CIR.0000076180.03211.BD CrossRefGoogle Scholar
- 38.Malek LA, Przyluski J, Spiewak M, Klopotowski M, Kostrzewa G, Kruk M, Ploski R, Witkowski A, Ruzyllo W (2010) Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology 117(2):81–87. https://doi.org/10.1159/000320093 CrossRefPubMedGoogle Scholar
- 39.Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103–113. https://doi.org/10.1016/j.clpt.2005.10.002 CrossRefPubMedGoogle Scholar